ERC – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:59 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg ERC – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Iohexol Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-iohexol-market-2021-2025/ Mon, 19 Jul 2021 02:43:41 +0000 https://www.cri-report.com/?post_type=product&p=13249 In 2020, due to the impact of COVID-19 on the hospital's overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%.

The post Investigation Report on China’s Iohexol Market 2021-2025 first appeared on CRI Report.

]]> Iohexol is a non-ionic X-ray contrast agent. Iohexol injection is suitable for intravascular and intracavitary injections in adults and children. In clinical angiography (cerebrovascular angiography, coronary angiography, peripheral and visceral angiography, ventricle angiography), CT-enhanced imaging of the head and body , Intravenous urography (IVP), arthrography, endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), hernia or fistula angiography, gastrointestinal angiography, “T “Pipeline radiography and so on. Iohexol was developed by Nycomed and was approved to enter the Chinese market in 1997. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several suppliers in the Chinese Iohexol market by 2020, of which Yangtze River Pharmaceutical Group Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Iohexol in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the hospital’s overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%. The CAGR of Iohexol sales value in the Chinese market from 2016 to 2020 is 0.45%.

CRI expects that with the relief of COVID-19, the sales of Iohexol in the Chinese market will have a restorative growth from 2021 to 2025. With the popularization of medical services in China and the advancement of medical technology, the demand for iodine and a non-ionic X-ray contrast agent in Chinese medical industry has gradually expanded, and sales value are expected to continue to grow from 2021 to 2025.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Iohexol market
  • – Sales value of China’s Iohexol 2016-2020
  • – Competitive landscape of China’s Iohexol market
  • – Prices of Iohexol in China
  • – Prices of Iohexol in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Iohexol market
  • – Prospect of China’s Iohexol market from 2021 to 2025

The post Investigation Report on China’s Iohexol Market 2021-2025 first appeared on CRI Report.

]]>